INTEGRATED BIOPHARMA INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that INTEGRATED BIOPHARMA INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jun 30, 2018 | $43.71M | Sep 12, 2018 |
| FY2018 | Jun 30, 2017 | $46.95M | Sep 12, 2018 |
| FY2013 | Jun 30, 2013 | $33.62M | Sep 30, 2013 |
| FY2013 | Jun 30, 2012 | $36.60M | Sep 30, 2013 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 30, 2017 | $46.95M | Sep 1, 2017 |
| FY2017 | Jun 30, 2016 | $42.21M | Sep 1, 2017 |
| FY2016 | Jun 30, 2015 | $37.49M | Sep 2, 2016 |
| FY2015 | Jun 30, 2014 | $33.68M | Sep 4, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $808.0K | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $112.0K | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | ($34.0K) | Sep 20, 2024 |
| FY2023 | Jun 30, 2022 | $3.84M | Sep 15, 2023 |
| FY2022 | Jun 30, 2021 | $8.01M | Sep 13, 2022 |
| FY2021 | Jun 30, 2020 | $4.11M | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | $1.69M | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | $679.0K | Aug 29, 2019 |
| FY2018 | Jun 30, 2017 | $2.35M | Sep 12, 2018 |
| FY2017 | Jun 30, 2016 | $958.0K | Sep 1, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $2.02M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $251.0K | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $120.0K | Sep 20, 2024 |
| FY2023 | Jun 30, 2022 | $2.75M | Sep 15, 2023 |
| FY2022 | Jun 30, 2021 | $5.78M | Sep 13, 2022 |
| FY2021 | Jun 30, 2020 | $3.26M | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | $2.70M | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | $1.69M | Aug 29, 2019 |
| FY2018 | Jun 30, 2017 | $3.19M | Sep 12, 2018 |
| FY2017 | Jun 30, 2016 | $2.11M | Sep 1, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $24.90M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $26.21M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $25.43M | Sep 20, 2024 |
| FY2023 | Jun 30, 2022 | $25.25M | Sep 15, 2023 |
| FY2022 | Jun 30, 2021 | $25.44M | Sep 13, 2022 |
| FY2021 | Jun 30, 2020 | $22.94M | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | $19.79M | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | $14.57M | Aug 29, 2019 |
| FY2018 | Jun 30, 2017 | $15.20M | Sep 12, 2018 |
| FY2017 | Jun 30, 2016 | $13.95M | Sep 1, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $4.58M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $6.97M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $6.57M | Sep 20, 2024 |
| FY2023 | Jun 30, 2022 | $6.68M | Sep 15, 2023 |
| FY2022 | Jun 30, 2021 | $11.11M | Sep 13, 2022 |
| FY2021 | Jun 30, 2020 | $16.88M | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | $17.90M | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | $19.80M | Aug 29, 2019 |
| FY2018 | Jun 30, 2017 | $21.13M | Sep 12, 2018 |
| FY2017 | Jun 30, 2016 | $22.28M | Sep 1, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $20.32M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $19.24M | Sep 23, 2025 |
| FY2025 | Jun 30, 2023 | $18.86M | Sep 23, 2025 |
| FY2024 | Jun 30, 2022 | $18.58M | Sep 20, 2024 |
| FY2023 | Jun 30, 2021 | $14.33M | Sep 15, 2023 |
| FY2022 | Jun 30, 2020 | $6.07M | Sep 13, 2022 |
| FY2021 | Jun 30, 2019 | $1.89M | Sep 2, 2021 |
| FY2020 | Jun 30, 2018 | ($5.24M) | Sep 23, 2020 |
| FY2019 | Jun 30, 2017 | ($5.93M) | Aug 29, 2019 |
| FY2018 | Jun 30, 2016 | ($8.33M) | Sep 12, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 20, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Sep 15, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Sep 13, 2022 |
| FY2021 | Jun 30, 2020 | 0 | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | 0 | Aug 29, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Sep 12, 2018 |
| FY2017 | Jun 30, 2016 | 0 | Sep 1, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 20, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Sep 15, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Sep 13, 2022 |
| FY2021 | Jun 30, 2020 | 0 | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | 0 | Aug 29, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Sep 12, 2018 |
| FY2017 | Jun 30, 2016 | 0 | Sep 1, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.62M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $1.68M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $1.32M | Sep 20, 2024 |
| FY2023 | Jun 30, 2022 | $331.0K | Sep 15, 2023 |
| FY2022 | Jun 30, 2021 | $210.0K | Sep 13, 2022 |
| FY2021 | Jun 30, 2020 | $402.0K | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | $475.0K | Sep 23, 2020 |
| FY2019 | Jun 30, 2018 | $228.0K | Aug 29, 2019 |
| FY2019 | Jun 30, 2017 | $132.0K | Aug 29, 2019 |
| FY2018 | Jun 30, 2016 | $395.0K | Sep 12, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Jun 30, 2023 | $0 | Sep 15, 2023 |
| FY2023 | Jun 30, 2022 | $101.0K | Sep 15, 2023 |
| FY2022 | Jun 30, 2021 | $3.64M | Sep 13, 2022 |
| FY2021 | Jun 30, 2020 | $8.34M | Sep 2, 2021 |
| FY2020 | Jun 30, 2019 | $9.65M | Sep 23, 2020 |
| FY2019 | Jul 1, 2018 | $3.62M | Aug 29, 2019 |
| FY2019 | Jun 30, 2018 | $9.34M | Aug 29, 2019 |
| FY2018 | Jun 30, 2017 | $10.12M | Sep 12, 2018 |
| FY2017 | Jun 30, 2016 | $10.45M | Sep 1, 2017 |
| FY2016 | Jun 30, 2015 | $9.12M | Sep 2, 2016 |